SecBot SecBot
8-K ·Filed Nov 3, 2026

RYTM

RHYTHM PHARMACEUTICALS, INC.
BULLISH
Impact 6/10
Horizonmonths Processed13d 15h ago SEC0001628280-26-069106
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong U.S. launch trajectory for IMCIVREE in acquired HO, with 29% sequential revenue growth and expanding prescriber base, supports continued top-line acceleration. The $750M term loan facility provides substantial capital to fund pipeline advancement, including Phase 3 trials for bivamelagon in both acquired HO and Prader-Willi syndrome, while the LG Chem amendment reduces future royalty drag. Monitor European country-level launches beginning in 2027 and Japan launch uptake as additional catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

IMCIVREE

▲ Bullish Named in this 8-K
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

Price Chart

Loading chart...

Executive Summary

Rhythm Pharmaceuticals reported Q3 2026 product revenue of $92.1M, well above the $84.6M consensus, driven by a strong U.S. launch of IMCIVREE in acquired hypothalamic obesity. Net loss per share of -$0.61 beat the -$0.74 consensus estimate. The company also secured a $750M term loan facility and amended its bivamelagon license with LG Chem, reducing the royalty rate to 1% in exchange for $350M in fixed payments.

Key Financial Metrics

EPS
−$0.61
est −$0.74 · +17.6%
Revenue
$92.1M
est $84.6M · +8.9% · +79.6% YoY
Rating
beat

Key Facts

  • Q3 2026 net product revenue of $92.1M, up 29% sequentially from Q2 2026 and 80% YoY from $51.3M in Q3 2025
  • Net loss attributable to common stockholders of -$42.4M, or -$0.61 per share, compared to -$54.3M or -$0.82 per share in Q3 2025
  • More than 700 patient start forms for IMCIVREE in acquired HO as of September 30, 2026, from more than 500 prescribers
  • Entered into a five-year term loan facility providing access to up to $750M, with an initial $250M draw
  • Amended bivamelagon license with LG Chem: $350M in fixed payments over four years to reduce royalty to 1% on MC4R portfolio sales
  • Cash, cash equivalents and short-term investments of $320.9M as of September 30, 2026, excluding the $250M loan draw and $70M LG Chem payment
  • 2026 Non-GAAP Operating Expense guidance narrowed to $360M-$380M from prior $363M-$397M

Financial Impact

Q3 revenue of $92.1M beat consensus of $84.6M by 8.9%; EPS of -$0.61 beat consensus of -$0.74 by 17.6%

revenueepscash_position

Risk Factors

  • Dependence on successful commercial execution of IMCIVREE in acquired HO, a newly approved indication
  • Significant increase in SG&A expenses (up 27% YoY) related to U.S. and Japan launches, which may pressure margins
  • Execution risk for Phase 3 trials of bivamelagon and RM-718, and potential for clinical setbacks
  • $350M fixed payment obligation to LG Chem over four years adds to cash burn

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-069106
Document: 0001628280-26-069106-index-headers.html0001628280-26-069106
Document: 0001628280-26-069106-index.html0001628280-26-069106
Document: 0001628280-26-069106.txt0001628280-26-069106
8-K Data (Synthetic)0001628280-26-069106

Track record

26 reports on RYTM

Performance horizon

9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 Viewing No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (9h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026